Synchron has closed a $95 million Series D funding round to accelerate commercialization of the Stentrode — a brain-computer interface delivered through the jugular vein rather than open-skull surgery. The device lodges in a blood vessel adjacent to the motor cortex and records neural signals through the vessel wall, translating intended movements into digital commands. The round was led by NVIDIA’s NVentures, with participation from Khosla Ventures and other existing investors.
Why the Endovascular Approach Matters
Traditional intracortical BCIs require a neurosurgeon to open the skull, retract the dura, and physically implant electrode arrays into brain tissue — a procedure with meaningful surgical risk, scarring, and signal degradation over time as the brain responds to the foreign device. Synchron’s endovascular approach eliminates craniotomy entirely. The Stentrode is pushed through a catheter into a blood vessel near the motor cortex, where it expands and locks into position against the vessel wall, recording from outside the blood-brain barrier.
The procedure takes under two hours. No skull is opened. Patients go home the next day.
Synchron clinical trial data, NEJM (2023)
What This Means For The Future
The competitive landscape for BCIs is heating up — Neuralink received FDA IDE approval in 2023, Precision Neuroscience is building ultra-thin cortical arrays, and now Synchron is moving toward commercialization with a lower surgical bar than any competitor. Each approach involves tradeoffs between signal quality and procedural safety. What’s clear is that neural interfaces are moving from research tools to clinical products on a timeline measured in years, not decades.
Sources: Synchron press release · NEJM (2023) · Crunchbase
Credit: Sumaid pal Singh Bakshi on Unsplash